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Introduction
The dopamine receptors belong to the G-protein-coupled re-
ceptor (GPCR) superfamily. They are membrane proteins with
seven transmembrane helices (TM1–7), and are involved in
second-messenger signal-transduction cascades via the gua-
nine binding proteins (G proteins). Based on their structure,
pharmacology, and transduction pathways, the dopamine re-
ceptors are grouped into two subfamilies: the D1-like (D1 and
D5) and the D2-like (D2,D 3, and D4) receptors. D1-like receptors
couple to the G protein Gs and stimulate adenylate cyclase,
which catalyzes the conversion of ATP to cyclic AMP, whereas
the D2-like receptors inhibit this enzyme via the G proteins Gi
and Go.
[1]
Dopamine receptor agonists have seen extensive clinical use
in the treatment of Parkinson’s disease (PD). For example, dop-
amine itself, administered as its biosynthetic precursor l-DOPA,
has been in use for more than four decades. The mixed D1/D2
receptor agonist apomorphine,
[2,3] as well as the orally bioavail-
able D2 agonists bromocriptine, pergolide, pramipexole, and
ropinirole, have all been shown to be useful in the treatment
of PD.
[4] The D2 receptor agonists in clinical use have far lower
efficacy than l-DOPA, and may also cause side effects such as
nausea and psychotic symptoms that are associated with D2
receptor activation. The critical role of D1 receptors in the treat-
ment of PD was discovered in the 1980s, with the selective ag-
onists SKF38393
[5] and CY-208-243.
[6] These drugs have only
modest therapeutic effect, but because both are partial ago-
nists, they led to the hypothesis that the beneficial antiparkin-
sonian activity depends on efficacy at D1. Interestingly, the full
and highly selective D1 receptor agonist ABT-431 (prodrug of
A86929) has been shown to have the same antiparkinsonian
efficacy as l-DOPA, with decreased neurological side effects.
[7]
In addition, Blanchet et al.
[8] reported that the well-known full
D1 agonist dihydrexidine (DHX) also shows a definite motor im-
provement in patients with PD, but with a narrow therapeutic
window.
The aim of this study was to use a combined structure and
pharmacophore modeling approach to extract information re-
garding dopamine D1 receptor agonism and D1/D2 agonist se-
lectivity. A 3D structure model of the D1 receptor in its agonist-
bound state was constructed with a full D1 agonist present in
the binding site. Two different binding modes were identified
using (+)-doxanthrine or SKF89626 in the modeling procedure.
The 3D model was further compared with a selective D1 ago-
nist pharmacophore model. The pharmacophore feature ar-
rangement was found to be in good agreement with the bind-
ing site composition of the receptor model, but the excluded
volumes did not fully reflect the shape of the agonist binding
pocket. A new receptor-based pharmacophore model was de-
veloped with forbidden volumes centered on atom positions
of amino acids in the binding site. The new pharmacophore
model showed a similar ability to discriminate as the previous
model. A comparison of the 3D structures and pharmacophore
models of D1 and D2 receptors revealed differences in shape
and ligand-interacting features that determine selectivity of D1
and D2 receptor agonists. A hydrogen bond pharmacophoric
feature (Ser-TM5) was shown to contribute most to the selec-
tivity. Non-conserved residues in the binding pocket that
strongly contribute to D1/D2 receptor agonist selectivity were
also identified; those were Ser/Cys
3.36, Tyr/Phe
5.38, Ser/Tyr
5.41,
and Asn/His
6.55 in the transmembrane (TM) helix region, to-
gether with Ser/Ile and Leu/Asn in the second extracellular
loop (EC2). This work provides useful information for the
design of new selective D1 and D2 agonists. The combined re-
ceptor structure and pharmacophore modeling approach is
considered to be general, and could therefore be applied to
other ligand–protein interactions for which experimental infor-
mation is limited.
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yet unknown, but extensive site-directed mutagenesis
[9–11] and
fluorescence
[10,12] studies have indicated the amino acid resi-
dues that are involved in the activation of GPCRs. The well-
conserved D(E)R
3.50Y
1 motif at the intracellular side of trans-
membrane helix 3 (TM3) is highly involved in receptor activa-
tion. In site-directed mutagenesis studies on the a1b
[9] and
b2
[10,11] adrenergic receptors, for example, it has been shown
that the interaction of TM3 with an acidic residue in TM6 sta-
bilizes the inactive receptor state. This “ionic lock” restrains the
location of TM6, as also shown for bovine
[14] and squid
[15] rho-
dopsin. In addition, mutation to the uncharged glutamine in
D(E)RY in rhodopsin results in a constitutively active opsin re-
ceptor.
[16]
Agonists that bind GPCRs have been suggested to be associ-
ated with the transition of helix conformations from the inac-
tive to active state.
[17–19] D1 and D2 receptor agonists share the
dopamine three-point pharmacophore: a hydrogen bond ac-
cepting/donating feature, an aromatic ring, and an amino
function. Generally, the selective D1 agonists are larger than
the D2 agonists and contain either primary or secondary amino
functions. In contrast, propyl substituents on the amine are fa-
vored in several D2 agonists, as the D2 receptor has a propyl
binding pocket.
[20] To the best of our knowledge, there is no
full D1 agonist that lacks the catechol motif, whereas there are
several D2 agonists known to have only a single hydroxy group
or other hydrogen bond accepting/donating functions. In addi-
tion, Payne et al.
[21] have shown that the non-hydroxylated di-
propylaminotetralin analogue (S)-DPAT is a full D2 agonist, but
with lower affinity than the hydroxylated agonist analogues.
It has been shown that D1 and D2 receptors are co-localized
as hetero-oligomers, both in the striatum and in the cortex.
[22]
The oligomeric receptors have a synergistic effect, and selec-
tive activation of either one of the receptors results in co-inter-
nalization of the hetero-oligomeric complex. It has also been
shown that D1 internalization efficacy is independent of both
the structural class and the affinity of the agonists.
[23,24] Howev-
er, although there is functional selectivity between the agonist
activation of adenylate cyclase and internalization, it seems
that only agonists with high efficacy can mediate internaliza-
tion.
[24]
In the present study we developed dopamine D1 receptor
models to better understand the molecular basis for selectivity
between full agonists and structurally similar inactive com-
pounds. We focused on characterizing the binding site for ago-
nists using available published binding selectivity data
[25–28]
and mutation data.
[29,30] Dopamine D1 receptor structure
models with all loops except the third intracellular loop (IC3)
were built by using the structure of the human b2 adrenergic
receptor (adrb2; PDB code: 2RH1) as template. The protein
structure models were compared and combined with the se-
lective dopamine D1 pharmacophore model published recently
by our group.
[31] The pharmacophore model was refined fur-
ther based on the binding pocket of the dopamine D1 receptor
(drd1) structure model. The drd1 model was compared with
the previously published drd2 structure model
[31] to study the
features that determine the selectivity between D1 and D2 re-
ceptor agonists. With this combined pharmacophore and re-
ceptor modeling approach, we can make optimal use of all
available structure–activity relationship (SAR), mutational, and
structural information to gain a more detailed understanding
of D1 agonism and agonist selectivity between D1 and D2 re-
ceptors.
Important amino acids for agonist binding to
the D1 receptor
The D1 dopamine receptor is not as well characterized as the
D2 or the b2 receptors, but like all catecholamine receptors it
contains an aspartic acid residue in TM3 (Asp103
3.32), which
forms a salt bridge with the basic amino group of the li-
gands.
[32] According to Pollock et al., the D1 receptor also in-
cludes a cluster of conserved serine residues (Ser198
5.42, 199
5.43,
and 202
5.46) in TM5, of which Ser198
5.42 contributes mainly to
the binding of dopamine and the partial agonist SKF38393.
[29]
It was shown that the binding of dopamine and SKF38393 to a
Ser198
5.42!Ala mutated receptor decreased more than 50-
and 14-fold, respectively. The study also included data on an
additional benzazepine derivative, the full agonist SKF82958
(fenoldopam), which together with SKF38393 is negatively af-
fected by a Ser199
5.43!Ala mutation (5- and 13-fold, respec-
tively). Dopamine is also affected considerably by this mutation
(10-fold), but on the other hand, it is even more sensitive to a
Ser202
5.46!Ala mutation. In a functional assay, SKF38393
showed greater potency toward the Ser202
5.46!Ala mutant
than toward wild-type, while the maximum intrinsic activity
was decreased,
[29] indicating that Ser202
5.46 is highly important
for efficacy. The study also included two structurally related
monohydroxylated benzazepines that act as antagonists; these
compounds are completely insensitive to the Ser202
5.46!Ala
mutation.
[13] These functional results indicate that the catechol
motif is essential for agonism and crucial for full D1 agonism,
0 To facilitate a comparison between different GPCRs, we use the indexing
method introduced by Ballesteros and Weinstein,
[13] where the most conserved
residue in every transmembrane (TM) helix is given the index number 50. For
example, the Arg residue in the highly conserved DRY motif at the cytoplas-
mic end of TM3 is denoted Arg
3.50; the other residues in TM3 are then indexed
relative to this position, with the previous residue as Asp
3.49, and the subse-
quent as Tyr
3.51. In addition, the absolute number of each residue in the
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5.46 is re-
quired for receptor activation. The D1 receptor has one addi-
tional serine residue (Ser197
5.41) in the same region, but it is
most likely oriented toward the membrane and thereby not
accessible for direct ligand binding.
Tomic et al.
[30] investigated dopamine binding to drd1 with
two double mutations in the orthosteric binding site
(Ser199
5.43!Val/Ser202
5.46!Ala and Cys106
3.35!Ala/
Ser107
3.36!Gly). As expected, the serine double mutation re-
sults in a drastic loss in binding affinity. However, dopamine
binding affinity was also decreased (sixfold) with the other
double mutation. The Ser107
3.36 residue is located one turn
down in the membrane relative to Asp103
3.32. The correspond-
ing serine mutation (Ser
3.36!Ala) in the 5-HT2B receptor result-
ed in a 30-fold decrease in binding affinity for 5-HT. However,
the potent 5-HT receptor partial agonist LSD is unaffected by
the mutation.
[33,34] Almaula et al.
[33] suggested that the amino
function of 5-HT interacts with both Ser
3.36 and Asp
3.32, whereas
LSD is sterically hindered to form these simultaneous interac-
tions. In addition, an alternative mutation at this position
(Ser
3.36!Cys) decreased the binding of 5-HT, but not as much
as did the Ser
3.36!Ala mutation. Ser
3.36 is conserved between
5-HT2A/2B and the D1 receptor, whereas the D2 receptor has a
cysteine residue at this position. In drd1 there is an additional
amino acid (Thr108
3.37) in TM3 that is accessible for ligand
binding. According to site-directed mutagenesis studies on
Thr
3.37 in the adrenergic a1B receptor (ada1b), this residue, to-
gether with Ser
3.36, is important for receptor activation.
[35]
No mutation studies involving the hydrophobic amino acids
in TM6 of drd1 are available. However, because this motif is
well conserved among the GPCRs it can be expected that the
D1 agonists make similar interactions with these amino acids
as do agonists of other monoaminergic receptors. Based on
mutational studies on drd2
[36] and SAR data, in combination
with modeling of the a2A adrenergic receptor,
[37] we expect
that Phe289
6.52 in drd1 interacts via a face-to-edge p–p interac-
tion with the aromatic catechol function of the agonist.
[36,37] In
addition, the hydrophobic residues Trp285
6.48 and Phe288
6.51
are expected to be accessible for ligand interaction, in analogy
with the D2 receptor.
[38] Asn
6.55 is conserved between drd1 and
the template structure (adrb2) and has been shown to be im-
portant for agonist binding in adrenergic b2 receptors.
[39] This
asparagine residue is believed to bind to the b-OH group of
adrb2 agonists.
[39] Although D1 agonists do not contain this
function, Asn292
6.55 may still be important for agonist recogni-
tion, either directly or indirectly. Manivet and co-workers
[34]
demonstrated that Asn
6.55 in the 5-HT2B receptor is involved in
direct or indirect 5-HT binding, while Ser
5.43 (Ser199
5.43 in D1)i s
not. This is in agreement with mutational studies on the D1 re-
ceptor, where the endogenous ligand is less affected by this
specific mutation than by other mutations in the serine clus-
ter.
[29]
As in all monoaminergic receptors, drd1 has a disulfide
bridge that connects Cys186 in the extracellular loop 2 (EC2)
with Cys96
3.25 in TM3 (EC2-SS-TM3); this constrains the loop on
top of the binding site crevice. The b2 adrenergic receptor
(adrb2) and the dopamine D1 receptor (drd1) have an equal
number of amino acids in the stretch between EC2-SS-TM3
and TM5, which is one more than the number of residues pres-
ent in the corresponding stretch in drd2. This makes the por-
tion of EC2 closest to the ligand binding site less constrained
than in drd2, which may, therefore, allow larger substituents to
point toward the extracellular side of the receptor. In addition,
the amino acid sequences differ significantly in the stretch
(CDSSLS, drd1; CIIAN-, drd2; Figure 1) between the disulfide
bridge and TM5, which may be crucial contributors to the D2/
D1 receptor agonist selectivity.
Figure 1. The refined multiple sequence alignment of the human adrenergic b2 receptor (adrb2, 2RH1) and the dopamine D1 (drd1) and D2 (drd2) receptors.
The adrb2 (DSC) bars indicate the transmembrane (TM) helix regions and the second extracellular loop helix (EC2 Helix) in the adrb2 structure. The lysozyme
in adrb2 and the third intracellular loop (IC3) in drd1 and drd2 between TM5 and TM6 were excised; this is indicated with a dashed line. The strikethrough
amino acid stretch WYRAT was cut out in the template structure. The green ring at the N terminus of TM5 in the drd2 sequence indicates the gap caused by
the smaller number of amino acids between the cysteine bridge (EC2-SS-TM3) and TM5. Amino acids marked in dark blue indicate fully conserved positions,
medium blue residues have highly similar physicochemical character, and light blue residues have less similar physicochemical character. The conserved cys-
teine bridge between TM3 and EC2 (EC2-SS-TM3) is indicated. The most conserved residue in each helix is marked with the index 50.
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Multiple sequence alignment and manual adjustments
A multiple sequence alignment of the human adrenergic b2
(adrb2, PDB code: 2RH1), drd1, and drd2 was performed by
using Clustal W (version 2.0.11).
[40] The program predicted the
alignment of the first five helices correctly, but not TM6 and
TM7, as the third cytoplasmic loop in drd2 is considerably
longer than in adrb2. The removal of the third intracellular
loop (IC3) in drd2 allowed a satisfactory alignment of the re-
maining conserved helical regions (TM6–7; see alignment in
Supporting Information figure 1).
The binding pocket is defined by amino acids within 3.5  
of the D1 receptor agonist doxanthrine, which was used as en-
vironment
2 during the homology modeling procedure. The ob-
tained Clustal W alignment was carefully checked in the non-
conserved positions close to the binding site and in loop re-
gions. Manual adjustments in some parts of the sequence
alignments were made with the purpose of improving the final
homology model (Figure 1). The following adjustments were
made:
TM3: The sequence PFG in drd1 in EC1 is moved toward the
N terminus of TM3 to fill a gap in that region.
TM4 and EC2: The amino acid stretch WYRAT (strikethrough
in Figure 1) between TM4 and the EC2 helix in adrb2 is
cut out in the template to allow the longer loop in the
drd1 model to find a more reasonable conformation. In
addition, the C terminus of TM4 in adrb2 contains weak
helix-forming amino acids (MH), whereas the corre-
sponding amino acids in D1 (LS) are stronger helical for-
mers. The removal of the WYRAT stretch in the tem-
plate thus allowed the program to freely predict the
secondary structure at the extracellular end of TM4.
The sequence similarity between adrb2 and drd1 in the
manually adjusted alignment was 36% in total, 43% in the TM
helix region, and 67% in the binding pocket (the correspond-
ing sequence similarity between drd1 and drd2 is 34, 43, and
55%, respectively).
D1 receptor homology modeling
The D1 homology model was built with the high-resolution b2
receptor structure (2RH1) as template. Modeling was per-
formed with the MOE software package
[41] (version 2009.10)
using the Amber99
[42] force field with an R-field solvation
model. See reference [31] for methodology details.
A proposed D1 receptor–agonist model and comparison
with the published selective D1 agonist pharmacophore
model
The D1 homology model was developed in a similar manner as
described in the preceding paper for the construction of the
D2 model.
[31] During generation of the homology model, the
potent and full D1 agonist (+)-doxanthrine
[26] (DOX) was pres-
ent in the binding site. DOX is a chromane-based analogue of
dihydrexidine (DHX), but unlike DHX, it is selective for D1 re-
ceptors.
[26] Twenty structure models were generated, and for
each model the side chain conformations were sampled three
times to give a total of 60 models. The backbone structure of
the generated drd1 models differed considerably in the C-ter-
minal part of TM4, in the EC2 close to the disulfide bridge, and
around the IC1 loop, but particularly in EC3. The amino acid
side chain conformations also differed in these regions. Such
differences were also observed in helical regions where more
than one optimal packing solution is possible.
The structure quality of the receptor models was evaluated
with the MOE evaluation features.
[41] For example: 1) bond
lengths, bond angles, and dihedral angles of the protein back-
bone; 2) Ramachandran plots of f–y dihedrals (General, Gly-
cine, Proline and pre-Proline [for explanations see plot for the
final model in figure 2 of the Supporting Information]); and
3) side chain rotamer quality. The focus was directed toward
the binding site region and the important agonist key interact-
ing amino acids. One dopamine D1 receptor homology model
with desirable geometry was selected for further preparation.
Hydrogen atoms were added to the ligand, and the ionization
and tautomeric states of the ligand–receptor complex were de-
termined. The complex was refined further by energy minimi-
zation with DOX present in the binding site with motion re-
strictions on all heavy atoms. This step was followed by an un-
constrained energy minimization. The final model was subject-
ed to detailed analysis and comparison with the recently pub-
lished D1 agonist pharmacophore model generated in our
research group.
[43]
The geometry of the key interacting pharmacophore fea-
tures was in good agreement with the positions of the corre-
sponding interacting amino acids in the homology model. In
contrast to the D2 case, good alignment of the pharmacophore
feature (Ser-TM5) with the serine cluster of the receptor was
obtained.
[31] The excluded volumes, however, did not fully re-
flect the shape of the binding site. A new version of the phar-
macophore with protein structure-based positioning of the ex-
cluded volumes was constructed. When introducing the ex-
cluded volumes of the new D1 pharmacophore model we dis-
covered that the D1 agonists may bind in two distinct binding
modes involving two different receptor binding site conforma-
tions. The ligands SKF89626, a super-agonist with an intrinsic
activity of 120%
[44] (Figure 2) and zelandopam (Figure 3) have
similar scaffolds, in which the catechol ring is linked via a
single bond to a bicyclic motif. All full D1 agonists that we
found in the literature contain a catechol function, and when
these aromatic rings are aligned, the binding mode of
SKF89626
[45] and zelandopam
[46] differ from the remaining set
0 The environment atoms (for example ligand structures and/or structural
water molecules) are specified by the user and are included in the homology
modeling procedure.
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have the bicyclic motif oriented perpendicular to the catechol.
In evaluating the rotational energy of the dihedral angle be-
tween the ring systems in SKF89626, we found that the energy
barrier to planarity was ~8 kcalmol
 1 (Supporting Information
figure 3). In an initial pharmacophore screen of the set of li-
gands, SKF89626 and zelandopam clashed into excluded vol-
umes corresponding to amino acids in TM6. Dinapsoline
(Figure 6 below) also had steric clashes in this region. There-
fore, different side chain rotamers of Phe288
6.51 were evaluated
to create space for dinapsoline, SKF89626, and zelandopam.
An energy minimization of the DOX-generated D1 homology
model with SKF89626 present in the binding site resulted in
the movement of Val317
7.39 toward Phe288
6.51 and Trp285
6.48.
A subsequent unconstrained energy minimization retained
this conformation. This modification of the model does not
affect the binding mode of DOX. The exact positions of fea-
tures, relative to the new set of structure-based excluded vol-
umes, were optimized based on pharmacophore hit rate of ac-
tives and inactives.
The typical monoaminergic key interactions, that is, the ionic
interaction to Asp103
3.32, the hydrogen bonds to the serine res-
idues (Ser198
5.42 and Ser202
5.46) and the face-to-edge p–p inter-
action with Phe289
6.52, are present in the D1 receptor–agonist
complexes (Figure 2). The distance from the oxygen atom in
the para-hydroxy group of SKF89626 to the oxygen in the hy-
droxy group of Ser202
5.46 is 2.7  , and the O-H-O(Ser202
5.46)
angle is 1788. In addition, the para-hydroxy group forms a hy-
drogen bond with Thr108
3.37 (d=2.7  , a=1768). The oxygen
atom in the corresponding meta position interacts with
Ser198
5.42 with a distance of 2.8   between the heavy atoms
and an O-H-O(Ser198
5.42) angle of 1668.
Ser199
5.43 is 4.6   away from the oxygen in the meta-hydroxy
group of SKF89626 and therefore does not interact directly
with the ligand, but instead forms a hydrogen bond with
Asn292
6.55. This is in agreement with the findings by Pollock
and co-workers
[29] that agonist binding is least sensitive for
mutations of Ser199
5.43 in the serine cluster. The basic amino
group of the ligand interacts almost symmetrically with both
oxygen atoms in Asp103
3.32 and forms a salt bridge with N O
distances of 2.7 and 2.9  , and N-H-O(Asp103
3.32) angles of
1588 and 1308. Ser107
3.36, which was shown to be important
for agonist binding in both the drd1
[30] and 5-HT2A receptors,
[33]
is directed toward the binding crevice and interacts with the
backbone carbonyl of Asp103
3.32. One of the hydrogen atoms
in the amino function of SKF89626 is just outside the defined
distance to form a hydrogen bond with Ser107
3.36 (d=4.6  ,
a=1758). Phe289
6.52, which has proven to be important for
agonist binding and activation of GPCRs,
[36,37] forms a face-to-
edge p–p interaction with the catechol motif of the ligand
(Figure 2). In addition, the position of the thiophene moiety of
SKF89626 is stabilized by the aromatic/hydrophobic cluster in
TM6 and TM7, which includes residues Phe288
6.51, Phe289
6.52,
Trp285
6.48, Val317
7.39, and Trp321
7.43 (Figure 2). Two of the
amino acids in EC2 (Ser188 and Leu190), which were found to
be important for agonist binding and activation of GPCRs,
[47,48]
are directed downward into the binding site crevice and can
thus make additional interactions with the ligand.
Evaluation of the selected D1 agonist-induced receptor
model
The final SKF89626-minimized D1 receptor model showed
good structural quality (Ramachandran plots are shown in
figure 2 of the Supporting Information) and had an RMSD in
relation to the template structure of 2.78   for Ca and 1.94  
for Ca of the TM region. The volume of the binding pocket is
495  
3. The model was investigated and evaluated further
using the Procheck program.
[49] With the exclusion of glycines
and prolines, 86% of the residues belonged to the most fa-
vored region of the Ramachandran map, 16% in the allowed,
and 1% in the generously allowed region according to Pro-
check. No residues belonged to disallowed regions. All main
chain and side chain geometries were designated to the
“better” class. Eight close contacts were identified, all between
the receptor and the ligand, of which five included hydrogen
atoms involved in hydrogen bonds and one from the face-to-
edge p–p interaction between Phe289
6.52 and the ligand. Close
contacts are defined as pairs of non-bonded atoms within a
distance of 2.6   from one another.
Figure 2. Schematic view of the interactions between the full agonist
SKF89626 and the dopamine D1 receptor homology model. The typical cate-
cholamine agonist–receptor key interactions with Asp103
3.32, Ser198
5.42, and
Ser202
5.46 are shown. The meta-hydroxy group of SKF89626 interacts via hy-
drogen bonding with Ser198
5.42, and the para-hydroxy group interacts with
Ser202
5.46. In addition, the para-hydroxy also forms a hydrogen bond to
Thr108
3.37. Phe289
6.52 forms a face-to-edge p–p interaction with the agonist,
and a methyl–p interaction with Ile104
3.33 is formed as well. Polar residues
are shown in purple, whereas hydrophobic residues are in green. Blue
shades indicate ligand–receptor solvent accessibility.
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The excluded volumes of the D1 pharmacophore model were
rearranged in the same way as for the D2 pharmacophore
model,
[31] and were based on the shape of the agonist binding
pocket. Thus, excluded volumes were introduced over the hy-
drogen atoms in amino acids that are located within 3   of the
ligand, including those involved in intermolecular hydrogen
bonding. Due to the discovery of the two different binding
modes, two ligand–receptor complexes, SKF89626 and DOX,
were used to identify the excluded volume positions. The ini-
tial radii of the excluded volumes were selected from the
van der Waals radii (vdWr) proposed by Bondi,
[50] (i.e. 1.2   for
aliphatic and 1.0   for aromatic, hydroxy, and amine [polar] hy-
drogen atoms). The sizes of the excluded volumes were tuned
manually until the pharmacophore model was sufficiently dis-
criminating. The final radii were 1.5   for aliphatic and 1.3   for
aromatic and polar hydrogen atoms. Excluded volumes cover-
ing the aromatic rings in aromatic amino acid residues were in-
troduced to account for face-to-edge clashes between aromat-
ic ring systems (Figure 4). The center of the volume is located
at the center of mass of the ring (r=2.5  ). The alignment of
the feature part of the pharmacophore model in relation to
the set of new excluded volumes derived from the receptor
model was tuned manually and evaluated by the hit rate of
the ligand training set. The model providing the best discrimi-
Figure 3. Selected full and partial D1 receptor agonists and structurally similar inactives screened against the new protein structure based pharmacophore
model. For a more detailed account of the set, see reference [43].
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pharmacophoric features do not superimpose perfectly with
the positioning of SKF89626, but the orientation of the fea-
tures is still in good agreement with the key interacting amino
acids (i.e., AspTM3, SerTM5 and Aro superimposed with
Asp103
3.32, Ser198
5.42, and Phe289
6.52, respectively, in the recep-
tor model; Figure 4). The new refined pharmacophore model
was screened against two conformational ensembles of D1 li-
gands that were generated with both MMFF(S)
[51] (MOE)
[41] and
OPLS
[52] (MacroModel)
[53] force fields, using Born solvation
(water). The initial screen of the new pharmacophore model
based on the drd1 receptor model showed similar results as
those obtained with the previously published pharmacophore
model
[31] (Table 1, structures shown either in Figure 3 or in ref-
erence [31]).
Evaluation of the D1 agonist pharmacophore model
The set of D1 ligands used in the previously published pharma-
cophore modeling study,
[43] supplemented with some novel
compounds described in detail below (15 full and 6 partial ag-
onists, and 10 structurally similar inactives; Figure 3) were
screened against the new protein structure based pharmaco-
phore model. Of the OPLS-generated set of ligand conforma-
tions, all but A70360 of the full agonists (14/15), and all but
two (4/6) of the partial agonists (A77641 and CY-208-243) fit
into the model. In addition, the model excluded all except two
(2/10) of the inactives (rotigotine and nPr-DHX; Table 1). The
D2-selective agonist nPr-DHX, which is defined as inactive in
this study, shows low D1 receptor affinity (IC50=651 nm,E C 50>
10
4 nm) and moderate efficacy (36%).
[27] The best hit of nPr-
DHX adopts a conformation with a relative energy of 3.4 kcal
mol
 1. All other ligands that hit the pharmacophore have a
best-hitting conformation with lower relative energy than nPr-
DHX. The hit conformation of the D1 inactive ligand rotigotine
had a relative energy of 1.9 kcalmol
 1 and an RMSD of 0.72,
which is the highest value of all pharmacophore hits. In addi-
tion, the number of hits relative to the number of conforma-
tions was low: 2/56 for nPr-DHX and 13/486 for rotigotine.
To further evaluate the model, we screened the pharmaco-
phore model against the same ligand set, but the conforma-
tions were generated with MMFF(S), which resulted in two
more pharmacophore hits of the inactives ((R)-NPA and cis-
DHX), but with unfavorable energy, hit rate, and RMSD
(Table 1). In addition, one more active ligand was excluded: ze-
landopam. Interestingly, one conformation of the active ligand
A70360 fit the pharmacophore with a high relative energy,
whereas none of the conformations of its enantiomer A70108
did (Figure 5A). This is in contrast to the OPLS-generated con-
formers, where A70108 fit, but A70360 was excluded. The
reason why they are on the border of matching the pharmaco-
phore model may be reflected by the fact that A70360 is a full
agonist, but with only low affinity, whereas its enantiomer
A70108 is a potent partial agonist (IA=60%).
[25]
Other notable results are the differences in receptor interac-
tions made by the DHX aza analogues 1–3 (Figure 5) in the D1
receptor model,
[28] for which the nitrogen atom in the most
potent and full agonist 1 may form a hydrogen bond with
Ser188 in EC2 (Supporting Information figure 4). The distance
between the heavy atoms in the hydrogen bond is 4.3   and
the N-H-O(Ser188) angle is 1398, which is not considered to be
an optimal hydrogen bond. However, because Ser188 is locat-
ed in the loop it is more flexible, and therefore able to change
its conformation; otherwise a water molecule may mediate the
interaction. Analogue 2 has slightly less affinity than 1, but
shows full efficacy for the D1 receptor. Finally, analogue 3 has
even lower affinity and decreased efficacy as well. In the phar-
macophore hits of 3, the nitrogen atom points toward the hy-
drophobic Leu190 residue located in EC2. Interestingly, 3 is the
most potent analogue at the D2 receptor with a similar affinity
as DHX.
[28] The corresponding residue to Leu190 in drd2 is an
asparagine (Asn186), whereas the Ser188 in drd1 corresponds
to Ile184, which may reflect the D1/D2 binding selectivity of the
aza analogues.
Figure 4. Top (left) and side view (right) of the new receptor-based pharmacophore model superimposed onto the D1 structure model. The transmembrane
helix 6 (TM6) and the hydrogen atoms of the interacting amino acids, together with the corresponding excluded volumes, are not shown. The conformation
of SKF89626 is taken from the ligand–receptor model complex, while the relative positions of the pharmacophore features are tuned to generate the best hit
rate.
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[54] studied dinapsoline analogues and dis-
covered that the 4-OH- and 6-Et-dinapsoline ana-
logues (Figure 6) showed a similar affinity as dinap-
soline, but the 6-Et analogue had enhanced intrinsic
activity. Bonner et al.
[55] recently published a novel
series of octahydrobenzo[h]isoquinolines, of which
the most potent compound (4, Figure 6) shows
higher affinity and similar efficacy for the D1 receptor
than do DHX and doxantrine. The cis analogue that
lacks the phenyl group, compound 5, is considered
inactive and is discriminated by the pharmacophore
model, whereas compound 4 matches nicely
(Table 1).
Table 1. Pharmacophore model search results from the new and old D1 agonist pharmacophore models using two different conformational ensembles of
the set of active and inactive ligands.
New pharmacophore model Old pharmacophore model
Ligand MOE stochastic search
Born solvation,
MMFF94(S)
[a]
MacroModel serial torsion
search
GB/SA solvation, OPLS2005
[b]
MOE stochastic search
Born solvation,
MMFF94(S)
[a]
MacroModel serial torsion
search
GB/SA solvation, OPLS2005
[b]
DE
[c] RMSD
[d] #c/#h
[e] DE
[c] RMSD
[d] #c/#h
[e] DE
[c] RMSD
[d] #c/#h
[e] DE
[c] RMSD
[d] #c/#h
[e]
Doxanthrine Full 0.5 0.60 2/1 0.0 0.11 14/14 0.0 0.12 2/2 0.0 0.11 14/6
SKF89626 Full 0.1 0.61 4/2 0.0 0.63 20/6 0.1 0.61 4/2 0.0 0.63 20/6
( )-A86929 Full 0.0 0.54 10/6 0.0 0.52 73/58 0.0 0.54 10/10 0.5 0.12 73/36
A77636 Full 1.4 0.30 3/1 0.0 0.26 11/7 0.0 0.28 3/2 0.0 0.26 11/7
A70360 Full 1.5 0.65 7/1 13/0 0.0 0.67 7/5 2.1 0.67 13/5
Zelandopam Full 4/0 0.0 0.63 40/13 4/0 2.9 0.63 40/2
SKF82958
[f] Full 3.8 0.47 22/1 2.2 0.40 50/6 1.8 0.41 22/1 0.0 0.43 50/8
1 Full 1.6 0.59 2/1 1.6 0.61 6/2 0.0 0.22 2/2 0.0 0.13 6/4
2 Full 0.0 0.23 2/2 0.2 0.62 12/6 0.0 0.23 2/2 0.0 0.12 12/6
Dinapsoline Full 0.0 0.39 1/1 0.0 0.45 4/4 0.0 0.39 1/1 0.0 0.45 6/4
Dopamine Full 0.0 0.66 6/1 0.0 0.64 20/8 0.0 0.66 6/1 0.0 0.64 20/8
DHX Full 0.8 0.63 2/1 0.0 0.13 14/14 0.0 0.23 2/1 0.0 0.13 14/8
4
[g] Full 0.0 0.55 2/2 0.0 0.56 16/8
4-OH-Dinapsoline
[g] Full 0.0 0.36 1/1 0.0 0.46 8/5
6-Et-Dinapsoline
[g] Full 0.0 0.37 6/3 0.0 0.46 16/16
A77641 Partial 3/0 11/0 3/0 2.8 0.67 11/2
A70108 Partial 6/0 0.0 0.56 11/7 0.0 0.71 6/3 0.0 0.72 11/7
3 Partial 0.0 0.62 2/2 0.9 0.61 8/4 2/0 8/0
CY-208-243 Partial 3/0 1/0 3/0 1/0
SKF38393 Partial 0.4 0.68 5/2 0.0 0.47 20/16 0.0 0.43 5/3 0.0 0.62 20/10
Apomorphine Partial 0.0 0.61 2/1 0.0 0.62 4/2 0.0 0.61 2/1 0.0 0.62 4/2
(+)-A86929 inactive 10/0 41/0 10/0 49/0
Ro21-7767
[f] Inactive 4/0 8/0 4/0 8/0
cis-DHX Inactive 5/0 12/0 2.7 0.62 5/1 3.4 0.62 12/4
( )-DHX inactive 0.8 0.74 2/1 8/0 0.8 0.74 2/1 8/0
Rotigotine
[f] inactive 1.3 0.73 186/5 1.9 0.72 486/13 3.6 0.69 186/2 486/0
(R)-NPA
[f] Inactive 2.5 0.60 6/1 27/0 6/0 27/0
Sumanirole Inactive 5/0 4/0 5/0 4/0
nPr-DHX
[f] inactive 1.3 0.42 17/2 3.4 0.43 56/2 17/0 56/0
Quinpirole Inactive 4/0 9/0 4/0 9/0
5 inactive 2/0 8/0
[a] The energy cutoff for conformations generated in MOE is 4 kcalmol
 1. [b] The energy cutoff for conformations generated in MacroModel is
16.7 kJmol
 1 (~4 kcalmol
 1). [c] The lowest relative energy [kcalmol
 1], with respect to the most stable conformer in the ensemble, for the conformers
that fit the pharmacophore model. [d] Root of the mean square distance between the center of the pharmacophore features and their matching ligand an-
notation points. [e] #c: number of conformations generated for the respective method; #h: number of conformations that hit the pharmacophore model.
[f] The amine is tertiary and therefore considered chiral, and two different configurations have been used in the modeling. [g] The compounds are new in
this study and therefore were not screened against the previously published pharmacophore model.
Figure 5. The potent partial D1 agonist A70108 (left) together with its enantiomer, the
full but less potent agonist A70360. DHX and its three aza analogues 1–3 are shown at
right.
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models and corresponding agonist pharmacophore models
The D1 homology model has an RMSD in relation to the corre-
sponding D2 model of 2.2   for Ca and 1.4   for Ca in the
transmembrane region. Thus, the dopamine receptor models
are more similar to each other in the TM region than they are
to the template structure (drd1–adrb2: 2.8   for all Ca and
1.9   for Ca in the TM region; drd2–adrb2: 2.1   for all Ca and
1.5   for Ca in the TM region). An overlay of the two models is
shown in Figure 7. The orthosteric binding pocket, defined as
amino acids within 3.5   of the corresponding agonists, is lo-
cated between TM2, 3, 5, 6, and 7, whereas EC2 lines the top
of the binding crevice. The volume of the binding pocket of
drd1 is 495  
3, whereas it is considerably smaller (371  
3) for
drd2. The radii of the optimized excluded volumes of the phar-
macophore models are 1.5   for aliphatic and 1.3   for aromat-
ic and polar hydrogen atoms in drd1, and respectively 2.1 and
1.9   in drd2. This indicates that the models probably underes-
timate the actual size difference between the receptor binding
sites.
The optimized positions of features, relative to the new set
of structure-based excluded volumes in the D1 pharmacophore
model, are shifted downward, corresponding to a deeper bind-
ing mode in the receptor compared with the corresponding D2
model. This is in agreement with the involvement of Ser
3.36 in
D1 agonist binding, as discussed above. There are 22 amino
acids that constitute the binding site, 10 of which are not con-
served between the receptors and thus could be expected to
contribute to agonist selectivity.
Figure 6. The agonist dinapsoline together with the octahydrobenzo[h]iso-
quinoline analogues 4 and 5; compound 4 is a potent full D1 agonist, and 5
is inactive.
Figure 7. Two orthogonal views of the dopamine D1 (blue) and D2 (yellow) receptor models together with the corresponding full agonists (R)-2-OH-NPA (blue)
and SKF89626 (yellow) present in their binding sites. The typical monoaminergic key interacting amino acid residues are shown explicitly. The structures differ
particularly in the second and the third extracellular loops (EC2 and EC3), but also in the transmembrane (TM) region, where important interacting amino
acids are positioned.
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3.32, drd2 has a valine residue,
whereas drd1 has a slightly bulkier isoleucine. One turn down
relative to Asp
3.32, a serine residue (Ser107
3.36) is positioned in
drd1 and a cysteine (Cys118
3.36) in drd2. Cysteine has an inferior
hydrogen bonding capacity to that of serine, and hydrophilic
elements are therefore less favorable in D2 ligands (such as the
DHX analogue DOX). DOX is a selective potent D1 agonist, and
it contains an ether function that points toward Ser/Cys
3.36.I n
our drd1 receptor model there is a hydrogen bond between
Ser107
3.36 and the backbone carbonyl in Asp103
3.32, whereas
Cys118
3.36 is rotated into the drd2 binding pocket and prevents
the deeper binding mode (Figure 8). The D2 agonist pharmaco-
phore model has a forbidden volume (ExclO) in this region,
which excludes oxygen atoms and thereby prevents DOX from
matching the model. In addition, the majority of the D1 ago-
nists contain a primary or secondary amine which can more
easily form hydrogen bonds with Ser107
3.36 without steric
clashes. Almaula et al.
[33] suggested that the amino function of
5-HT interacts with both Ser
3.36 and Asp
3.32 in the 5-HT2A recep-
tor, whereas the partial agonist LSD has a tertiary amino func-
tion and is thereby sterically hindered from forming these si-
multaneous interactions. This may be the reason for the ab-
sence of full D1 agonists with tertiary amino groups. There is
one exception—SKF82958—which has an allyl substituent on
the amine. Interestingly, the N-methyl-substituted analogue is
a partial agonist, whereas the secondary amine analogue is a
full agonist. SKF82958 has a chlorine atom in the meta position
of the aromatic ring which has been shown to enhance both
affinity and efficacy.
[23]
In TM5 the serine residues that are part of the binding site
are conserved between drd1 and drd2, but one turn toward
the extracellular side of the receptor, drd1 has a tyrosine and
drd2 a phenylalanine residue. TM5 in the drd2 model is rotated
slightly inward toward the ligand binding site relative to the
drd1 model, which makes the serine residues in drd2 less opti-
mally positioned for catechol interaction. This is also reflected
in the D2 agonist pharmacophore model, in which the hit rate
was retained when the Ser-TM5 feature was redefined from es-
sential to optional. In the D1 pharmacophore model the Ser-
TM5 feature must be essential for retaining the hit rate.
Both receptors contain a highly conserved hydrophobic face
in TM6, but they differ in one important position, where drd2
has a histidine and drd1 an asparagine residue, the latter
being conserved with the template structure. In mutagenesis
studies His393
6.55 has been shown to be highly involved in ag-
onist binding in drd2, but the corresponding Asn292
6.55 in drd1
has not been studied. As described above, Asn293
6.55 in adrb2
has been shown to be involved in agonist binding, and in the
drd2 model His393
6.55 is accessible for ligand interaction,
whereas Asn292
6.55 in drd1 is rotated toward TM5 and interacts
with Ser199
5.43 (Figure 8). The additional polar interaction with
His393
6.55 in the D2 receptor may be one reason for D2 agonism
with aromatic substitutions other than the catechol function.
D1 agonists can only make polar interactions in this region
with the TM5 serines, and for that a catechol function seems
to be optimal. The phenylalanine residue (Phe
6.52), which forms
a face-to-edge p–p interaction with the agonists, is positioned
almost identically in the two models. The rotamers of the tryp-
tophan residue (Trp
6.48) one turn down from Phe
6.51 relative to
the membrane differ to some extent between the receptors.
Trp386
6.48 in drd2 is rotated in the direction toward TM7. Trp
6.48
in drd1 cannot adopt the same conformation as in drd2 due to
steric hindrance of the non-conserved Trp321
7.43 residue in
TM7, which is rotated out toward the ligand (Figure 8). The
corresponding Tyr416
7.43 in the D2 receptor interacts with
Asp114
3.32 and is rotated toward TM2.
The rotation gives rise to a cavity referred to as the propyl
pocket, which is localized between the residues Val83
2.53,
Cys118
3.36, Trp386
6.48, Thr412
7.39, and Tyr416
7.43. This cavity is not
present in the drd1 model (Figure 8 and 9).
[31] The geometrical
differences in TM6 and TM7 between D1 and D2 may be the
Figure 8. Side view of the superposed dopamine D1 (blue) and D2 (yellow)
receptor models. Transmembrane helix 6 (TM6) is cut out. The conserved
tryptophan residue in TM6 that differs in conformation, together with the
non-conserved amino acids in TM3, TM6, and TM7, are included and colored
by corresponding receptor. Together with the amino acids in TM2, TM3, and
TM7, Trp
6.48 forms the D2-characteristic propyl pocket, which is a major con-
tributor to D1/D2 selectivity. Tyr
7.43 in drd2 interacts with Asp
3.32, whereas the
corresponding residue (Trp
7.43) is unable to make that bond and is instead
rotated toward TM6 and Trp
6.48. His
6.55 interacts with the meta-hydroxy
group of the D2 agonist (R)-2-OH-NPA (yellow), while the corresponding
Asn
6.55 forms a hydrogen bond with Ser
5.43. The D1 agonist SKF89626 (blue)
binds deeper in the binding crevice and makes interactions with both Ser
3.36
and Asp
3.32.
Figure 9. Representation of the solvent-accessible surface of the D2 (left)
and D1 (right) receptors, as viewed from the binding pocket in the direction
of the D2-characteristic propyl pocket region. The N-propyl functional group
of (R)-2-OH-NPA is included to illustrate the shape difference between the
receptors.
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nists and only one for D2 agonists (Figure 8).
The second extracellular loop (EC2) differs considerably be-
tween the two dopamine receptor models and is also most
likely a major contributor to D1/D2 agonist selectivity. The EC2
in drd1 is more flexible than in drd2 due to the longer amino
acid chain between the cysteine bridge (EC2-SS-TM3) and TM5.
This could explain the larger substituents in the D1 agonists in
the direction toward the extracellular side. Another reason for
selectivity could be the switch in polarity of the two amino
acids in EC2 pointing downward into the binding crevice
(Leu190 in drd1 corresponds to Asn186 in drd2, and Ser188 in
drd1 corresponds to Ile184 in drd2; Figure 8 and Supporting
Information figure 4). We suggest that the extended EC2
stretch in combination with a deeper binding mode in drd1 is
the reason for the larger average size of D1 agonists relative to
D2 agonists.
Conclusions
A 3D structure model of the D1 receptor was developed and
compared with our previously published selective D1 agonist
pharmacophore model.
[31] The pharmacophore model was
aligned and compared with the receptor model. The positions
of the pharmacophore features were in agreement with the D1
agonist key interactions identified in the receptor model and
were supported by mutation data. Furthermore, a new refined
pharmacophore model guided by the shape of the binding
site in the receptor model was developed. The pharmacophore
and the protein structure models were constructed based on
structural information together with binding and mutation
data. The combined modeling approach helps to identify
strengths and weaknesses in both models. The D1-selective
and potent agonist doxanthrine was positioned in the binding
site during construction. The 3D structure model was modified
slightly to allow an alternate agonist binding mode. The 3D
structure model of the receptor showed good geometric quali-
ty, and the typical dopamine receptor agonist key interactions
were present.
The D1 agonist pharmacophore and the receptor models
were compared with the corresponding D2 agonist models to
identify differences and thereby pinpoint reasons behind D1/D2
receptor agonist selectivity. We suggest that the D1 agonists
bind deeper in the binding site, which may be a consequence
of interactions with Ser107
3.36. The serine residue is positioned
one turn down from Asp
3.32, which forms a salt bridge with the
amino function in the agonist. Interactions between Ser107
3.36
and tertiary amino functions in D1 receptor agonists might be
difficult, owing to steric hindrance. The selective drd2 agonists
often have a propyl-substituted tertiary amino function, with
the propyl group fitting well into a hydrophobic region pres-
ent in the D2 receptor binding pocket (Figure 9).
The combined pharmacophore and receptor modeling ap-
proach enabled optimal use of all relevant data on receptor
subtype selectivity, such as SAR, mutational, protein structure,
and sequence data for each receptor subtype. This approach
has provided a strong basis for the interpretation of the re-
quirements for dopamine D1/D2 selectivity based on what is
known in the field to date.
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